Study Population

This study included 3757 patients with ischemic cardiomyopathy based on medical records and follow-up registrations at the First Affiliated Hospital of Xinjiang Medical University between December 2009 and November 2021. Exclusion criteria were as follows: (1) patients with no T2DM; (2) patients with severe acute infection, malignancy, severe liver dysfunction, severe renal dysfunction, and suspected familial hypertriglyceridemia [TG ≥ 5.65 mmol/L]; (3) patients with a history of coronary artery bypass, congenital heart disease or severe valvular requiring cardiac surgery. (4) Patients with incomplete clinical or follow-up data. The study excluded 2243 patients based on the exclusion criteria. Finally, 1514 patients were enrolled in this study. Medical records and/or a telephone interview with patients or their family members were used to determine the short or long-term prognosis of patients. Studies involving human participants were reviewed were approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (approval number: S220722-25) and followed the Declaration of Helsinki. Patients/participants provided written informed consent for their participation in this study. Individuals provided written informed consent for the publication of any potentially identifiable images or data included herein. Figure 1 shows the flow chart for participant inclusion and exclusion.

Flow chart of the study population enrollment.